Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe
The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.
Tag: Idiopathic Hypersomnia
All
Latest
All
Latest
New Data Suggests Best Orexin Receptor Agonists Are Still to Come
As the first orexin-2 receptor agonist for narcolepsy nears FDA approval, a preclinical compound shows promise for its higher potency.
All
Latest
Lumryz Drives Avadel’s Q4 Revenue Surge and Plans for 2025 Growth
Avadel’s once-nightly narcolepsy treatment Lumryz saw significant Q4 growth, prompting expanded sales and patient support efforts for 2025.
Centessa Appoints Neuropsychiatrist as Chief Medical Officer
The new CMO brings over 30 years of experience in neuroscience and drug development to Centessa as it advances its orexin receptor 2 agonist portfolio.
Read More
Jazz Pharmaceuticals CEO to Retire, Succession Search Underway
Bruce Cozadd, co-founder, chairperson, and CEO of Jazz, announced plans to retire as CEO upon the appointment of a successor by the end of 2025.
Read More
Meeting to Tackle Drug Development Challenges for Idiopathic Hypersomnia
The Illuminate Hypersomnia Adjunct Scientific Meeting on Feb 13, 2025, will address challenges in idiopathic hypersomnia drug development.
Read More
Survey Reveals Power of Social Connections for Narcolepsy and IH Patients
A global survey reveals that peer connections significantly improve support and adjustment for individuals with narcolepsy and idiopathic hypersomnia.
Read More
Centessa Launches Phase 2 Trial of ORX750 for Narcolepsy and IH
Centessa Pharmaceuticals has initiated a phase 2 trial of ORX750, an oral orexin receptor 2 agonist designed to treat narcolepsy type 1, type 2, and idiopathic hypersomnia.
Read More
Centessa Prioritizes Orexin Agonist Program Following Positive Data
Centessa Pharmaceuticals discontinues SerpinPC, an investigational hemophilia B therapy, to reallocate resources to its orexin receptor program.
Read More
Avadel’s Narcolepsy Treatment Lumryz Brings in $50 Million in Q3
During the quarter, Lumryz saw increased patient uptake, expanded to pediatric use, and secured a legal victory affirming its clinical superiority, as the company continues its phase 3 trial in idiopathic hypersomnia.
Read More
Narcolepsy Insights from Alkermes Presented at Psych Congress and NEI Congress
Alkermes’ presentations feature research on its investigational treatment ALKS 2680 in narcolepsy and insights on the burden of living with the condition.
Read More
Jazz Hits Record Q3 Revenue with Strong Growth in Sleep Portfolio
Jazz Pharmaceuticals reported record third-quarter 2024 revenues of over $1.05 billion, with strong performance from its sleep portfolio.
Read More
Definitive Merger Agreement Reached Between NLS and Kadimastem
The companies will combine to focus on advancing NLS’ orexin platform and Kadimastem’s cell therapy program.
Read More
Jazz Presents New Phase 4 Data on Xywav’s Impact on Narcolepsy and IH
Top-line results show improvements on excessive daytime sleepiness and key polysomnography outcomes.
Read More
Harmony’s Wakix Surpasses $2B in Revenue, Data Shows Promise for IH Treatment
Wakix surpassed $2 billion in cumulative revenue since its 2019 launch for adult narcolepsy, with Harmony on track to submit a supplemental new drug application for idiopathic hypersomnia in Q4.
Read More
Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025
Alkermes’ Q3 update reveals progress for ALKS 2680, an orexin 2 receptor agonist aimed at treating narcolepsy and idiopathic hypersomnia, with phase 2 trial completions expected in 2025.
Read More
What Exactly Is Software as a Medical Device?
With increasing FDA clearances for standalone software in sleep medicine, “software as a medical device” is becoming a key term. Experts explain what SaMD entails and explore its unique advantages and challenges.
Read More
ORX142 Promotes Wakefulness at Very Low Doses, Preclinical Data Shows
In non-human primate models, oral administration of ORX142 promoted sustained increases in wakefulness at the lowest dose tested.
Read More